Abstract:
Rhamnetin has a wide usageduetoits anti-inflammatory, anti-carcinogenicand anti-oxidantproperties. In this study, the
effects of different doses of Rhamnetin on ascitetumor were investigated in the Ehrlich Assit Tumor (EAT) model originating from
mouse breast adenocarcinoma and developed in Balb / c mice.
Inthisstudy 10Balb / c mice were used each group, six of them were in stock animals and the others were in ascitestumor groups.
EAT cells (1x106 EAT cells) taken from all stock mice were injected intraperitoneally. 200 μg /kg rhamnetin was administered
intraperitoneally to the treatment groups of animals with ascites tumor for 10 days. At theend of the experiment, the animals were
decapitated and the hearts of the animals were removed and determined orhistological evaluation.
The histological results of hearttissues of ascitestumor-induced animals were observed to be less in the 200 μg / kg rhamnetin treated
group compared to the tumor control group than EAT cells (p <0.05).
It has beenshown in our study that rhamnetin has antitumoral effect on ascitetumor development with EAT cells.